Research programme: pain and neurological disorder therapeutics - CSIRO/NeuroDiscovery
Latest Information Update: 16 Sep 2011
At a glance
- Originator NeuroDiscovery
- Developer CSIRO; NeuroDiscovery
- Mechanism of Action Gap junction modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Neuralgia; Neurological disorders; Pain